Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Harrow Health Inc (HROW) achieves record Q3 revenue growth

Harrow Health Inc (HROW) reported strong Q3 performance with record revenue, driven by VEVYE and IHEEZO. The company is focused on sustainable growth, long-term vision, and value creation for stakeholders. Challenges include temporary inventory shortages and limited direct-to-consumer advertising plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow's wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. In commenting on the announcement, Mark L.

Harrow Launches Next-Generation Compounded Atropine Formulations

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the IHEEZO J‑code (J2403) will become effective April 1, 2023.

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products: ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®.

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations, in solution. The availability of Fortisite for in-office use represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.

Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

Apollo Global Management

Brunswick

ETRACS Linked to the Wells Fargo Business Development Company Index ETN

Chart Industries

mCloud Technologies Corp

Runway Growth Finance Corp

Saratoga Investment

As December 2022 comes to a close, we observe six new preferred stock / exchange-traded-debt (ETD) offerings during the month, offering annual yields ranging from 6.75% to 11.875%. Here is a comparison against the highest quality preferred stocks in our coverage universe, as ranked by our internal “CDx3 Compliance Score” metric.

Tough Preferred Stock IPO Environment Continues: 6 December 2022 Offerings

NASHVILLE, Tenn.--( BUSINESS WIRE )--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced top-line results of its Phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the company intends to request a meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of this study and the continued clinical development of MELT-300.

Melt Pharmaceuticals' MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced the pricing of its underwritten registered public offering of $35 million aggregate principal amount of 11.875% senior notes due 2027 (the “Notes”). Harrow has granted the underwriters a 30‑day option to purchase an additional $5.25 million aggregate principal amount of Notes in connection with the offering. The offering is expected to close on December 20, 2022, subject to customary closing conditions.

Harrow Secures Capital to Close Recently Announced Acquisition

Harrow Health is a founder-led eyecare company, the CEO holds 10% of the shares. It is moving up the value chain with a focus on branded products such as a recent (second) deal with Novartis.

Harrow Health Transaction Moves It Closer To The Big Leagues For 2023

Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic products from the Novartis group of companies. The Nashville, Tennessee-based eye care pharmaceutical company said the acquisition, when closed, will further expand Harrow's portfolio of branded pharma products and its ability to serve the US ophthalmic surgical and acute care markets.

Harrow Health forges agreement to acquire exclusive US rights to blockbuster Novartis eyecare drugs

NASHVILLE--( BUSINESS WIRE )--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it has commenced an underwritten registered public offering of $100 million aggregate principal amount of senior notes due 2027, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30‑day option to purchase an additional 15% of the principal amount of senior notes sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it priced an underwritten registered offering of 2,376,426 shares of its common stock at a price of $10.52 per share for aggregate gross proceeds of $25 million. The offering is expected to close on or about December 16, 2022, subject to customary closing conditions.

Harrow Prices $25 Million Offering

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it has entered into a binding agreement for the acquisition of the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies (“Novartis”). This acquisition, when closed, will further expand and diversify Harrow's portfolio of branded pharmaceutical products and its ability to serve the U.S. ophthalmic surgical and acute care markets. Subject to customary closing conditions, this acquisition is expected to close in early 2023.

Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

NASHVILLE, Tenn. & KANSAS CITY, Mo.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expansion of their national product supply agreement to provide Harrow's entire formulary compounded ophthalmic products to iOR Partners' expanding office-based surgery locations across the United States.

Harrow and iOR Partners Expand National Product Supply Agreement

Sienna Harrow Health, Inc. (NASDAQ:HROW ) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Sahil Kazmi – B.

Harrow Health, Inc. (HROW) Q3 2022 Earnings Call Transcript

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (NASDAQ: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced results for the third quarter ended September 30, 2022. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com.

Harrow Announces Third Quarter 2022 Financial Results

Harrow Launches Atropine.com

Harrow Health, Inc. is a well-managed ophthalmic medicines business. The company has remained profitable for a number of years.

Harrow Health: Profitable Ophthalmic Business With Growth Potential

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close.

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (“Revelation”). Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow's non‑ophthalmic compounding business, incl

Harrow Sells Non-Ophthalmic Compounding Business

LEDGEWOOD, N.J.--(BUSINESS WIRE)---- $HROW--ImprimisRx, America's #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Fortisite, which includes a compounded combination antibiotic formulation (Tobramycin 1.5% and Vancomycin 5%) in solution,

ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for oc

News for Harrow Health Inc Stock (HROW)